ArticleFrontiers in endocrinology2025
Development and validation of a risk prediction model for 30-day readmission in elderly type 2 diabetes patients complicated with heart failure: a multicenter, retrospective study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamic evolution of readmission risk factors across short-, medium-, and long-term horizons in type 2 diabetes: a machine learning-based predictive modeling study with SHAP interpretability.Frontiers in endocrinology · 2026Article
- Development and Validation of a Nomogram-Based Risk Prediction Model for Diabetic Retinopathy in Elderly Adults with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elderly type 2 diabetes mellitus (T2DM) patients complicated with heart failure (HF) exhibit a high rate of 30-day readmission. Predictive models have been suggested as tools for identifying high-risk patients. Thus, we aimed to develop and validate a predictive model using multicenter electronic medical records (EMRs) data to estimate the risk of 30-day readmission in elderly T2DM patients complicated with HF. Methods: EMRs data of elderly T2DM patients complicated with HF from five tertiary hospitals, spanning 2012 to 2023, were utilized to develop and validate the 30-day readmission model. The model were evaluated using holdout data with the area under the receiver operating characteristic curve (AUROC), calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: A total of 1899 patients were included, with 955, 409, and 535 in the derivation, internal validation, and external validation cohorts, respectively. Pulmonary infections (odds ratio [OR]: 3.816, 95% confidence interval [CI]: 2.377-6.128, Conclusion: A 30-day readmission risk prediction model was developed and externally validated. This model facilitates the targeting of interventions for elderly T2DM patients complicated with HF who are at high risk of an early readmission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.